Biofilms and their role in the resistance of pathogenic Candida to antifungal agents.

  title={Biofilms and their role in the resistance of pathogenic Candida to antifungal agents.},
  author={Christophe d’Enfert},
  journal={Current drug targets},
  volume={7 4},
  • C. d’Enfert
  • Published 31 March 2006
  • Biology, Medicine
  • Current drug targets
Fungal pathogens of the genus Candida form biofilms on catheters and prosthetic devices. These three-dimensional structures composed of yeast and hyphal cells embedded in an extracellular matrix constitute an important pitfall in the management of disseminated Candida infections because of their intrinsic resistance to almost all antifungals in clinical use. Candida biofilms are especially resistant to azoles and amphotericin B but remain sensitive to the newly introduced echinocandins that… 
Interaction of Candida albicans Biofilms with Antifungals: Transcriptional Response and Binding of Antifungals to Beta-Glucans
It was observed that AMB physically bound C. albicans biofilms and beta-glucans, which have been proposed to be major constituents of the biofilm extracellular matrix and to prevent azoles from reaching biofilm cells, thus limiting their toxicity to these cells and the associated transcriptional responses.
Hsp90 Governs Dispersion and Drug Resistance of Fungal Biofilms
A novel mechanism regulating biofilm drug resistance and dispersion is established and that targeting Hsp90 provides a much-needed strategy for improving clinical outcome in the treatment of biofilm infections.
Pseudomonas aeruginosa secreted factors impair biofilm development in Candida albicans.
P. aeruginosa supernatant strongly reduced the ability of C. albicans to form biofilms on silicone, and expression of YWP1, which encodes a protein known to inhibit biofilm formation, was significantly increased.
The inhibitory activity of linalool against the filamentous growth and biofilm formation in Candida albicans.
Results indicate that linalool may have therapeutic potential in the treatment of candidiasis associated with medical devices because it interferes with the morphological switch and biofilm formation of C. albicans.
Small-molecule inhibitors of biofilm formation in laboratory and clinical isolates of Candida albicans.
Data indicate that the biofilm-forming capability of laboratory and clinical isolates of C. albicans, as well as the efficacy of BHT inhibitors against these different isolates, can differ dramatically, and should be an important aspect to consider when examining potentially new antifungal therapeutics.
Candida Albicans Biofilm as a Clinical Challenge
In women, vulvovaginal candidiasis is caused by Candida albicans and other species in the vagina and it may affect the quality of life and it is a major challenge for drug developers.
Biofilm formation in Candida glabrata: What have we learnt from functional genomics approaches?
The Yak1 kinase and the Swi/Snf chromatin remodeling complex have been shown to relieve the repression exerted by subtelomeric silencing on the expression of the EPA6 and EPA7 genes, thus allowing the encoded adhesins to exert their key roles in biofilm formation.
The characteristics of Aspergillus fumigatus mycetoma development: is this a biofilm?
Overall, A. fumigatus appears to possess the classical elements of biofilm growth, namely multicellularity, matrix production and sessile resistance.
Molecular characterization of Candida in the oral cavity and factors involved in biofilm formation and virulence
New Candida glabrata adhesin-like wall proteins are discovered; proteins that are involved in attachment to human tissues and/or medical implants and can play a role in biofilm formation and could be potential new targets for anti-adhesive antifungal drug development.